Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor - PubMed
3 hours ago
- #Senolytic
- #Reproducibility
- #Cellular Senescence
- Reevaluation of a GLS1 inhibitor and an anti-PD-1 antibody showed no significant reduction in p16INK4a-positive senescent cells or improvement in aging-related health parameters, contrary to earlier reports.
- The study emphasizes the importance of rigorous experimental design, standardized protocols, and independent validation for reliable senolytic drug development before clinical use.
- Cellular senescence, via the senescence-associated secretory phenotype (SASP), is recognized not only as tumor-suppressive but also as a potential driver of chronic inflammation and age-related diseases.
- Despite promising preclinical findings, concerns about reproducibility and generalizability of senolytic drugs remain, highlighting the need for cross-laboratory validation.
- The research did not aim to discredit previous work but to foster methodological rigor and transparency in the field of senescence and senolytics.